In renal cell carcinoma, combined low levels of VEGF and Apelin in sunitinib‐treated patient serum correlated with a 6‐fold longer progression‐free survival compared to patients with high levels of both VEGF and Apelin. This evidence concerns the gene APLN and renal cell carcinoma.